Cadila Healthcare gets 14 USFDA observations for Moraiya plant
The US Food and Drug Administration (USFDA) inspected the plant from April 22, 2019 to May 3, 2019, Cadila Healthcare said in a regulatory filing.
New Delhi: Drug firm Cadila Healthcare Friday said the US health regulator has issued 14 observations after inspecting its manufacturing facility at Moraiya in Ahmedabad.
The US Food and Drug Administration (USFDA) inspected the plant from April 22, 2019 to May 3, 2019, the company said in a regulatory filing.
"The inspection concluded with 14 observations. There were no repeat observations or data integrity related observations," it added.
Also Read: Cadila Healthcare subsidiary gets 5 observations from USFDA
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at email@example.com Contact no. 011-43720751 To know about our editorial team click here